Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

•P. aeruginosa susceptibility and CF exacerbation treatment response was studied.•Lung function response did not differ by P. aeruginosa antimicrobial coverage.•Weight response did not differ by P. aeruginosa antimicrobial coverage.•Future risk of exacerbation was not affected by P. aeruginosa antim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2021-03, Vol.20 (2), p.257-263
Main Authors: VanDevanter, Donald R., Heltshe, Sonya L., Hilliard, Jay B., Konstan, Michael W.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anti-Bacterial Agents - therapeutic use
Cystic fibrosis
Cystic Fibrosis - complications
Cystic Fibrosis - physiopathology
Female
Humans
Male
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Pseudomonas Infections - drug therapy
Pulmonary exacerbation
Respiratory Function Tests
Susceptibility testing
Symptom Flare Up
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•P. aeruginosa susceptibility and CF exacerbation treatment response was studied.•Lung function response did not differ by P. aeruginosa antimicrobial coverage.•Weight response did not differ by P. aeruginosa antimicrobial coverage.•Future risk of exacerbation was not affected by P. aeruginosa antimicrobial coverage.•Antimicrobial susceptibility test (AST) results did not predict treatment response. Background Antimicrobial susceptibility testing (AST) of bacterial isolates is a time- and resource-intensive procedure recommended by cystic fibrosis (CF) treatment guidelines for antimicrobial selection for pulmonary exacerbation (PEx) treatment. Methods We studied relationships between Pseudomonas aeruginosa (Pa) isolate AST results, antipseudomonal PEx treatments, and treatment responses as change in weight and percent predicted forced expiratory volume in 1 s (ppFEV1) as well as future antimicrobial treatment hazard for PEx occurring at a CF care center from 1999 through 2018. Treatments were categorized by “Pa coverage” as complete (all Pa isolates susceptible by AST to at least one administered agent), none (no isolates susceptible), incomplete (some, but not all isolates susceptible), and indeterminant (administered antipseudomonals not evaluated by AST). Weight and ppFEV1 responses were compared across Pa coverage categories using unadjusted and adjusted general estimating equations; hazard of future treatment was assessed by Cox and logistic regression. Results Among 3820 antimicrobial PEx treatment events in 413 patients with Pa, 62.6% (2390) had complete Pa coverage; 8.9% (340), 2.4% (99), and 26.2% (1000), had no, incomplete, and indeterminant Pa coverage, respectively. Mean baseline to follow-up weight change was +0.74 kg [95% CI 0.63, 0.86]; ppFEV1 change was +1.60 [1.29, 1.90]. Pa coverage category was not associated with significant differences in weight or ppFEV1 change or with future antimicrobial treatment hazard. Conclusions We did not observe superior responses for AST-defined complete Pa coverage treatments versus lesser coverage treatments, suggesting that AST may be of little utility in choosing antimicrobials for CF PEx treatment.
ISSN:1569-1993
1873-5010
DOI:10.1016/j.jcf.2020.05.008